The combination of Selinexor and Docetaxel in the phase I/II trial for KRAS‐mutant NSCLC showed some effect in TP53 wild‐type patients but exhibited limited efficacy in the overall patient population, along with high treatment toxicity (such as neutropenia, gastrointestinal discomfort, etc.).245. This evidence concerns the gene TP53 and non-small cell lung carcinoma.